Dec 10, 2020 · MYR GmbH is a private, commercial stage biotechnology company headquartered in Bad Homburg, Germany. The company is dedicated to the development of bulevirtide; bulevirtide is a first-in-class entry inhibitor which binds to …

Mar 4, 2021 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration.

Dec 10, 2020 · MYR GmbH is a private, commercial stage biotechnology company headquartered in Bad Homburg, Germany. The company is dedicated to the development of Bulevirtide; Bulevirtide is a first-in-class entry inhibitor which binds to …

Dec 10, 2020 · Under the terms of the sale and purchase agreement, Gilead will acquire MYR for approximately €1.15 billion in cash, payable upon closing of the transaction plus a potential future milestone ...

Dec 10, 2020 · Gilead Sciences bolstered its capabilities in treating Hepatitis and other liver diseases with the €1.15 billion ($1.4 billion) cash acquisition of Germany-based Myr GmbH, a company focused on developing therapies for the treatment of chronic hepatitis delta virus (HDV), the most severe form of viral hepatitis.

Dec 12, 2020 · FOSTER CITY, Calif. and BAD HOMBURG, Germany — Gilead Sciences, Inc. and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), announced that the companies have entered into a definitive agreement pursuant to which Gilead will …

Dec 10, 2020 · Gilead Sciences Inc said on Thursday it will acquire MYR GmbH for about 1.15 billion euros ($1.39 billion) in cash, giving it access to the German biotech company's treatment for a severe...

Dec 11, 2020 · Gilead Sciences has signed a definitive agreement to acquire German biotechnology company MYR for approximately €1.15bn ($1.4bn) in cash. According to the deal, MYR is also eligible for a potential future milestone payment of up to €300mn ($363m), upon closing of the deal.

MYR is a biotechnology company developing and commercilizing therapeutics for the treatment of chronic hepatitis B and D infections. View contacts for MYR GmbH to access new leads and connect with decision-makers.

Mar 4, 2021 · FOSTER CITY, Calif.-- (BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately...